Article
Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.
Cancer letters - 10 Apr 2022
Yan Rui, Fan Xiaona, Xiao Zeru, Liu Heshu, Huang Xuying, Liu Jian, Zhang Shucai, Yao Jiannan, An Guangyu, Ge Yang
Abstract excerpt
Lung adenocarcinoma is the most common form of lung cancer, accounting for 60% of non-small cell lung cancer (NSCLC) cases in Asian patients. Importantly, nearly half of these patients have epithelial growth factor receptor (EGFR) mutations. Though EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line therapy for NSCLC patients, the development of resistance reduces their efficiency and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.